H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Precigen today and set a price target of $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors surrounding Precigen’s potential and financial outlook. The imminent FDA decision on PRGN-2012, a treatment for recurrent respiratory papillomatosis (RRP), is a pivotal factor. The strong efficacy and safety data suggest a favorable outcome, which could make PRGN-2012 the first approved therapy for RRP, transforming Precigen into a commercial entity and establishing a new standard of care.
Additionally, Precigen’s proactive launch preparations, including collaboration with Eversana for commercialization, and targeting a significant cohort of prescribers, indicate readiness for market entry. Financial projections are optimistic, with expected revenues of $124M in 2026 and growth to $1.0B by 2033. The company’s current financial position, with sufficient cash reserves, supports ongoing operations. The valuation, based on a risk-adjusted net present value analysis, underpins the Buy rating with a 12-month price target of $6.00 per share.
According to TipRanks, Ramakanth is a 4-star analyst with an average return of 7.3% and a 38.00% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Eton Pharmaceuticals, Precigen, and Corcept Therapeutics.